An Open-Label, Multinational, Multicenter, Phase IIIB Study With Subcutaneus Administration Of Trastuzumab In Patient With Her2-Positive Early Breast Cancer To Evaluate Patient Satisfaction Read more about An Open-Label, Multinational, Multicenter, Phase IIIB Study With Subcutaneus Administration Of Trastuzumab In Patient With Her2-Positive Early Breast Cancer To Evaluate Patient Satisfaction
A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus Patients Intervention Study) Read more about A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus Patients Intervention Study)
AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS Read more about AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS
"A Phase IIIb, Single-arm Study to Evaluate the Safety and Immunogenicity ofArabio Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 56Years and Above in Saudi Arabia" Read more about "A Phase IIIb, Single-arm Study to Evaluate the Safety and Immunogenicity ofArabio Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 56Years and Above in Saudi Arabia"
"Randomized, Open Label, Non-inferiority Study of Micafungin Versus Standard Care for the Prevention of Invasive Fungal Disease in High Risk Liver Transplant Recipients" Read more about "Randomized, Open Label, Non-inferiority Study of Micafungin Versus Standard Care for the Prevention of Invasive Fungal Disease in High Risk Liver Transplant Recipients"
A Phase IIIb, Interventional, Multicentre, Multinational, Randomised, Open-label Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f® and Luveris® Starting on Day 1 vs. Day 6 in Women Between 36 and 42 Years of Age Undergoing Assisted Reproductive Technique (ART) Read more about A Phase IIIb, Interventional, Multicentre, Multinational, Randomised, Open-label Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f® and Luveris® Starting on Day 1 vs. Day 6 in Women Between 36 and 42 Years of Age Undergoing Assisted Reproductive Technique (ART)
A Phase 3b, open-labeled, randomized, parallel-group, multi-center study to evaluate the safety of novartis MenACWY Conjugate Vaccine when administered with routine infant Vaccinations to healthy Infants Read more about A Phase 3b, open-labeled, randomized, parallel-group, multi-center study to evaluate the safety of novartis MenACWY Conjugate Vaccine when administered with routine infant Vaccinations to healthy Infants
An open-Label, multicenter, expanded access study of Everolimus in Patients with advanced Nerouendocrine tumors. Read more about An open-Label, multicenter, expanded access study of Everolimus in Patients with advanced Nerouendocrine tumors.
Extending molecular responeses with Nilotinib in newly diagnosed chronic myeloid leukemia (CML) patients in chronic phase (ENESTxtnd) Read more about Extending molecular responeses with Nilotinib in newly diagnosed chronic myeloid leukemia (CML) patients in chronic phase (ENESTxtnd)
A multi-center open-label parallel group randomized controlled trial to compareiGlarLixi versus premixed insulin in patients with type 2 diabetes who have failedto achieve glycemic control with basal insulin and oral antidiabetic agents Read more about A multi-center open-label parallel group randomized controlled trial to compareiGlarLixi versus premixed insulin in patients with type 2 diabetes who have failedto achieve glycemic control with basal insulin and oral antidiabetic agents
